VIM and Parkinson disease: Despite the limited sample size (n = 5 per group), we noted a trend toward increased total vimentin levels in patients with PD using both vimentin antibodies (Fig. 7, E to F, left and right), in line with our findings in hiPSC-derived SNCADupl midbrain neurons.